PRPO – Precipio Inc

Float Short %

0.09

Margin Of Safety %

-30

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

24.02

Target Price

Analyst Recom

Performance Q

14.44

Relative Volume

0.28

Beta

1.12

Ticker: PRPO

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	PRPO	20.04	N/A	N/A	0
2025-11-11	PRPO	20.19	N/A	N/A	0
2025-11-12	PRPO	20.15	N/A	N/A	0
2025-11-13	PRPO	19.52	N/A	N/A	0
2025-11-14	PRPO	18.98	N/A	N/A	0
2025-11-17	PRPO	21.25	N/A	N/A	0
2025-11-18	PRPO	23.34	N/A	N/A	0
2025-11-19	PRPO	26.75	N/A	N/A	0
2025-11-20	PRPO	25.46	N/A	N/A	0
2025-11-21	PRPO	24.75	N/A	N/A	0
2025-11-24	PRPO	24.49	N/A	N/A	0
2025-11-25	PRPO	22.31	N/A	N/A	0
2025-11-26	PRPO	24.39	N/A	N/A	0
2025-12-01	PRPO	22.57	N/A	N/A	0
2025-12-02	PRPO	24.85	N/A	N/A	0
2025-12-03	PRPO	25.4	N/A	N/A	0
2025-12-04	PRPO	24.61	N/A	N/A	0
2025-12-05	PRPO	24	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	PRPO	20.24	-	-	-
2025-11-11	PRPO	20.19	-	-	-
2025-11-12	PRPO	20.68	-	-	-
2025-11-13	PRPO	19.94	-	-	-
2025-11-14	PRPO	19.22	-	-	-
2025-11-17	PRPO	21.01	-	-	-
2025-11-18	PRPO	22.93	-	-	-
2025-11-19	PRPO	26.25	-	-	-
2025-11-20	PRPO	25.98	-	-	-
2025-11-21	PRPO	24.57	-	-	-
2025-11-24	PRPO	24.00	-	-	-
2025-11-25	PRPO	22.28	-	-	-
2025-11-26	PRPO	24.28	-	-	-
2025-12-01	PRPO	22.57	-	-	-
2025-12-02	PRPO	24.56	-	-	-
2025-12-03	PRPO	25.48	-	-	-
2025-12-04	PRPO	24.95	-	-	-
2025-12-05	PRPO	24.02	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	PRPO	3.71	-2.40	0.03
2025-11-11	PRPO	3.71	-2.40	0.03
2025-11-12	PRPO	3.71	-2.40	0.10
2025-11-13	PRPO	3.71	-2.40	0.10
2025-11-14	PRPO	3.71	-2.40	0.10
2025-11-17	PRPO	3.71	4.58	0.09
2025-11-18	PRPO	4.07	4.58	0.09
2025-11-19	PRPO	3.75	4.58	0.09
2025-11-20	PRPO	3.75	4.58	0.09
2025-11-21	PRPO	3.78	4.58	0.09
2025-11-24	PRPO	-1.65	15.68	0.09
2025-11-25	PRPO	-1.65	15.68	0.09
2025-11-26	PRPO	-1.65	15.68	0.09
2025-12-01	PRPO	-2.43	15.89	0.09
2025-12-02	PRPO	-2.43	15.89	0.09
2025-12-03	PRPO	-2.43	15.89	0.09
2025-12-04	PRPO	-2.43	15.89	0.09
2025-12-05	PRPO	-2.43	15.89	0.09
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

-2.43

Institutional Transactions

15.89

Beta

1.12

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

16.84

Quality Score

Growth Score

Sentiment Score

100

Actual DrawDown %

86.9

Max Drawdown 5-Year %

-95.8

Target Price

P/E

Forward P/E

PEG

P/S

1.85

P/B

3.05

P/Free Cash Flow

71.33

EPS

-0.83

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-5.5

Relative Volume

0.28

Return on Equity vs Sector %

-36

Return on Equity vs Industry %

-19.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Precipio, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 54

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

stock quote shares PRPO – Precipio Inc Stock Price stock today

news today PRPO – Precipio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRPO – Precipio Inc yahoo finance google finance

stock history PRPO – Precipio Inc invest stock market

stock prices PRPO premarket after hours

ticker PRPO fair value insiders trading

PRPH – ProPhase Labs Inc

Float Short %

0.21

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.13

Target Price

Analyst Recom

Performance Q

-65.8

Relative Volume

1.13

Beta

-0.62

Ticker: PRPH

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	PRPH	0.2818	0.00	0.00	16835
2025-11-11	PRPH	0.2716	0.00	0.00	16861
2025-11-12	PRPH	0.268	0.00	0.00	16950
2025-11-13	PRPH	0.254	0.00	0.00	17027
2025-11-14	PRPH	0.28	0.00	0.00	17053
2025-11-17	PRPH	0.26	0.00	0.00	17058
2025-11-18	PRPH	0.2614	0.00	0.00	17091
2025-11-19	PRPH	0.2436	0.00	0.00	17093
2025-11-20	PRPH	0.188	0.00	0.00	17402
2025-11-21	PRPH	0.1878	0.00	0.03	17523
2025-11-24	PRPH	0.1795	0.00	0.00	13074
2025-11-25	PRPH	0.1736	0.00	0.00	13137
2025-11-26	PRPH	0.1828	0.00	0.00	13287
2025-12-01	PRPH	0.1912	0.00	0.00	13435
2025-12-02	PRPH	0.133	0.00	0.03	14271
2025-12-03	PRPH	0.1338	0.00	0.01	14330
2025-12-04	PRPH	0.1369	0.00	0.01	14458
2025-12-05	PRPH	0.1299	0.00	0.00	14508
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	PRPH	0.28	-	-	-
2025-11-11	PRPH	0.27	-	-	-
2025-11-12	PRPH	0.27	-	-	-
2025-11-13	PRPH	0.25	-	-	-
2025-11-14	PRPH	0.28	-	-	-
2025-11-17	PRPH	0.26	-	-	-
2025-11-18	PRPH	0.26	-	-	-
2025-11-19	PRPH	0.23	-	-	-
2025-11-20	PRPH	0.19	-	-	-
2025-11-21	PRPH	0.19	-	-	-
2025-11-24	PRPH	0.18	-	-	-
2025-11-25	PRPH	0.18	-	-	-
2025-11-26	PRPH	0.19	-	-	-
2025-12-01	PRPH	0.19	-	-	-
2025-12-02	PRPH	0.14	-	-	-
2025-12-03	PRPH	0.14	-	-	-
2025-12-04	PRPH	0.14	-	-	-
2025-12-05	PRPH	0.13	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	PRPH	0.00	-9.68	3.09
2025-11-11	PRPH	0.00	-9.68	3.09
2025-11-12	PRPH	0.00	-9.68	0.64
2025-11-13	PRPH	0.00	-9.68	0.64
2025-11-14	PRPH	0.00	-9.68	0.64
2025-11-17	PRPH	0.00	6.01	0.64
2025-11-18	PRPH	0.00	6.01	0.64
2025-11-19	PRPH	0.00	6.01	0.64
2025-11-20	PRPH	0.00	6.01	0.64
2025-11-21	PRPH	0.00	6.01	0.64
2025-11-24	PRPH	0.00	1.40	0
2025-11-25	PRPH	0.00	1.40	0.58
2025-11-26	PRPH	0.00	1.40	0.21
2025-12-01	PRPH	0.00	1.46	0.21
2025-12-02	PRPH	0.00	1.46	0.21
2025-12-03	PRPH	0.00	1.46	0.21
2025-12-04	PRPH	0.00	1.46	0.21
2025-12-05	PRPH	0.00	1.46	0.21
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

1.46

Beta

-0.62

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.2

Max Drawdown 5-Year %

-99.2

Target Price

P/E

Forward P/E

PEG

P/S

0.47

P/B

0.79

P/Free Cash Flow

EPS

-1.5

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-217.64

Relative Volume

1.13

Return on Equity vs Sector %

-634.8

Return on Equity vs Industry %

-618.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

ProPhase Labs, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 96

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today

news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance

stock history PRPH – ProPhase Labs Inc invest stock market

stock prices PRPH premarket after hours

ticker PRPH fair value insiders trading

NEO – Neogenomics Inc.

Float Short %

6.84

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.06

EPS Last/This Y

0.72

EPS This/Next Y

0.08

Price

11.9

Target Price

12.5

Analyst Recom

2.29

Performance Q

50.06

Relative Volume

0.27

Beta

1.57

Ticker: NEO

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	NEO	10.4	0.20	0.00	33158
2025-11-11	NEO	10.4	0.20	0.14	33276
2025-11-12	NEO	10.01	0.20	0.00	33230
2025-11-13	NEO	10.01	0.19	1.76	33921
2025-11-14	NEO	10.38	0.19	0.01	34071
2025-11-17	NEO	10.22	0.19	0.00	34193
2025-11-18	NEO	10.4	0.19	1.53	34185
2025-11-19	NEO	10.28	0.20	0.00	34257
2025-11-20	NEO	10.59	0.20	0.00	34083
2025-11-21	NEO	11.48	0.20	0.00	34028
2025-11-24	NEO	11.63	0.18	0.27	26356
2025-11-25	NEO	12.35	0.18	0.03	26602
2025-11-26	NEO	12.15	0.18	0.01	27161
2025-12-01	NEO	12.02	0.17	0.01	27307
2025-12-02	NEO	12.06	0.17	0.00	27490
2025-12-03	NEO	12.11	0.17	0.13	27480
2025-12-04	NEO	12.19	0.17	0.00	27539
2025-12-05	NEO	11.9	0.17	0.15	27655
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	NEO	10.40	5.8	-	0.10
2025-11-11	NEO	10.42	5.8	-	0.10
2025-11-12	NEO	10.01	5.8	-	0.10
2025-11-13	NEO	10.01	5.8	-	0.10
2025-11-14	NEO	10.34	5.8	-	0.10
2025-11-17	NEO	10.22	5.8	-	0.10
2025-11-18	NEO	10.40	5.8	-	0.10
2025-11-19	NEO	10.28	5.8	-	0.10
2025-11-20	NEO	10.60	5.8	-	0.10
2025-11-21	NEO	11.48	3.9	-	0.10
2025-11-24	NEO	11.63	3.9	-	0.10
2025-11-25	NEO	12.34	3.9	-	0.10
2025-11-26	NEO	12.14	3.9	-	0.10
2025-12-01	NEO	12.02	3.9	-	0.10
2025-12-02	NEO	12.07	3.9	-	0.10
2025-12-03	NEO	12.12	3.9	-	0.10
2025-12-04	NEO	12.19	3.9	-	0.10
2025-12-05	NEO	11.90	4.2	-	0.10
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	NEO	1.19	-3.78	5.20
2025-11-11	NEO	1.19	-3.78	5.20
2025-11-12	NEO	1.19	-3.78	5.73
2025-11-13	NEO	1.19	-3.78	5.73
2025-11-14	NEO	1.05	-3.78	5.73
2025-11-17	NEO	1.06	-3.39	5.73
2025-11-18	NEO	1.06	-3.39	5.73
2025-11-19	NEO	1.06	-3.39	5.73
2025-11-20	NEO	1.06	-3.39	5.73
2025-11-21	NEO	1.06	-3.39	5.73
2025-11-24	NEO	1.06	0.53	5.83
2025-11-25	NEO	0.68	0.53	5.83
2025-11-26	NEO	0.68	0.53	6.84
2025-12-01	NEO	0.27	0.04	6.84
2025-12-02	NEO	0.27	0.04	6.84
2025-12-03	NEO	0.27	0.04	6.84
2025-12-04	NEO	0.27	0.04	6.84
2025-12-05	NEO	0.27	0.04	6.84
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

0.04

Avg. EPS Est. Next Quarter

0.01

Insider Transactions

0.27

Institutional Transactions

0.04

Beta

1.57

Average Sales Estimate Current Quarter

188

Average Sales Estimate Next Quarter

187

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

80.7

Max Drawdown 5-Year %

-91.9

Target Price

12.5

P/E

Forward P/E

72.39

PEG

P/S

2.17

P/B

1.83

P/Free Cash Flow

EPS

-0.89

Average EPS Est. Cur. Y

0.1

EPS Next Y. (Est.)

0.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-16

Relative Volume

0.27

Return on Equity vs Sector %

-40.4

Return on Equity vs Industry %

-24.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NeoGenomics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2200

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

stock quote shares NEO – Neogenomics Inc. Stock Price stock today

news today NEO – Neogenomics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NEO – Neogenomics Inc. yahoo finance google finance

stock history NEO – Neogenomics Inc. invest stock market

stock prices NEO premarket after hours

ticker NEO fair value insiders trading

MYGN – Myriad Genetics, Inc.

Float Short %

8.68

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

0.13

EPS Last/This Y

1.42

EPS This/Next Y

0.06

Price

7.09

Target Price

8.06

Analyst Recom

Performance Q

2.6

Relative Volume

0.44

Beta

1.8

Ticker: MYGN

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	MYGN	6.49	0.05	0.00	3381
2025-11-11	MYGN	6.68	0.05	0.00	3380
2025-11-12	MYGN	6.55	0.05	0.00	3384
2025-11-13	MYGN	6.36	0.05	0.00	3384
2025-11-14	MYGN	6.72	0.05	0.00	3360
2025-11-17	MYGN	6.66	0.05	0.02	3373
2025-11-18	MYGN	6.62	0.05	0.00	3354
2025-11-19	MYGN	6.43	0.05	0.00	3354
2025-11-20	MYGN	6.89	0.05	0.03	3311
2025-11-21	MYGN	7.38	0.05	0.00	3288
2025-11-24	MYGN	7.72	0.03	0.00	1702
2025-11-25	MYGN	7.9	0.03	0.40	1711
2025-11-26	MYGN	7.61	0.04	0.18	1711
2025-12-01	MYGN	7.07	0.04	0.00	1699
2025-12-02	MYGN	7.02	0.04	4.50	1703
2025-12-03	MYGN	7.34	0.04	0.20	1713
2025-12-04	MYGN	7.33	0.04	0.00	1715
2025-12-05	MYGN	7.09	0.04	0.00	1715
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	MYGN	6.48	-104.9	425.7	0.01
2025-11-11	MYGN	6.68	-104.9	425.7	0.01
2025-11-12	MYGN	6.55	-104.9	425.4	0.01
2025-11-13	MYGN	6.36	-104.9	425.3	0.01
2025-11-14	MYGN	6.72	-125.3	425.9	0.01
2025-11-17	MYGN	6.66	-125.3	425.4	0.01
2025-11-18	MYGN	6.62	-125.3	425.5	0.01
2025-11-19	MYGN	6.44	-125.3	425.3	0.01
2025-11-20	MYGN	6.90	-125.3	426.0	0.01
2025-11-21	MYGN	7.37	-149.6	425.9	0.01
2025-11-24	MYGN	7.72	-149.6	425.8	0.01
2025-11-25	MYGN	7.91	-149.6	425.7	0.01
2025-11-26	MYGN	7.61	-149.6	425.3	0.01
2025-12-01	MYGN	7.06	-149.6	425.0	0.01
2025-12-02	MYGN	7.02	-149.6	425.5	0.01
2025-12-03	MYGN	7.33	-149.6	425.8	0.01
2025-12-04	MYGN	7.33	-149.6	425.5	0.01
2025-12-05	MYGN	7.09	-145.4	425.3	0.01
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	MYGN	0.00	-5.02	8.76
2025-11-11	MYGN	0.00	-5.02	8.76
2025-11-12	MYGN	0.00	-5.02	8.09
2025-11-13	MYGN	0.00	-5.02	8.09
2025-11-14	MYGN	0.00	-5.02	8.08
2025-11-17	MYGN	0.00	14.59	8.08
2025-11-18	MYGN	0.00	14.59	8.08
2025-11-19	MYGN	0.00	14.59	8.08
2025-11-20	MYGN	0.00	14.59	8.08
2025-11-21	MYGN	0.00	14.59	8.08
2025-11-24	MYGN	0.00	0.28	8.08
2025-11-25	MYGN	0.00	0.28	8.08
2025-11-26	MYGN	0.00	0.28	8.68
2025-12-01	MYGN	0.00	4.65	8.68
2025-12-02	MYGN	0.00	4.65	8.68
2025-12-03	MYGN	0.00	4.65	8.68
2025-12-04	MYGN	0.00	4.65	8.68
2025-12-05	MYGN	0.00	4.65	8.68
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

4.65

Beta

1.8

Average Sales Estimate Current Quarter

207

Average Sales Estimate Next Quarter

209

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

80.8

Max Drawdown 5-Year %

-89.5

Target Price

8.06

P/E

Forward P/E

121.51

PEG

P/S

0.8

P/B

1.77

P/Free Cash Flow

EPS

-4.33

Average EPS Est. Cur. Y

0.01

EPS Next Y. (Est.)

0.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-48.53

Relative Volume

0.44

Return on Equity vs Sector %

-134.3

Return on Equity vs Industry %

-118.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

425.3

Myriad Genetics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2700

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today

news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance

stock history MYGN – Myriad Genetics, Inc. invest stock market

stock prices MYGN premarket after hours

ticker MYGN fair value insiders trading

MTD – Mettler-Toledo International, Inc.

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol= #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol= &conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol= 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol= 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol= 589 450 ]

Sector:

Industry:

Employees:

stock quote shares MTD – Mettler-Toledo International, Inc. Stock Price stock today

news today MTD – Mettler-Toledo International, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MTD – Mettler-Toledo International, Inc. yahoo finance google finance

stock history MTD – Mettler-Toledo International, Inc. invest stock market

stock prices premarket after hours

ticker fair value insiders trading

GENE – Genetic Technologies Ltd. ADR

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=GENE #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=GENE &conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.76

Target Price

6.87

Analyst Recom

Performance Q

-14.99

Relative Volume

Beta

1.11

Ticker: GENE

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	GENE	0.765	N/A	N/A	0
2025-11-11	GENE	0.765	N/A	N/A	0
2025-11-12	GENE	0.765	N/A	N/A	0
2025-11-13	GENE	0.765	N/A	N/A	0
2025-11-14	GENE	0.765	N/A	N/A	0
2025-11-17	GENE	0.765	N/A	N/A	0
2025-11-18	GENE	0.765	N/A	N/A	0
2025-11-19	GENE	0.765	N/A	N/A	0
2025-11-20	GENE	0.765	N/A	N/A	0
2025-11-21	GENE	0.765	N/A	N/A	0
2025-11-24	GENE	0.765	N/A	N/A	0
2025-11-25	GENE	0.765	N/A	N/A	0
2025-11-26	GENE	0.765	N/A	N/A	0
2025-12-01	GENE	0.765	N/A	N/A	0
2025-12-02	GENE	0.765	N/A	N/A	0
2025-12-03	GENE	0.765	N/A	N/A	0
2025-12-04	GENE	0.765	N/A	N/A	0
2025-12-05	GENE	0.765	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=GENE 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.5

Max Drawdown 5-Year %

-97.7

Target Price

6.87

P/E

Forward P/E

PEG

P/S

1.24

P/B

2.89

P/Free Cash Flow

EPS

-1.83

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-156.76

Relative Volume

Return on Equity vs Sector %

-680.2

Return on Equity vs Industry %

-667.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=GENE 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=GENE 589 450 ]

stock quote shares GENE – Genetic Technologies Ltd. ADR Stock Price stock today

news today GENE – Genetic Technologies Ltd. ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch GENE – Genetic Technologies Ltd. ADR yahoo finance google finance

stock history GENE – Genetic Technologies Ltd. ADR invest stock market

stock prices GENE premarket after hours

ticker GENE fair value insiders trading

PRPO – Precipio Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PRPO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

PRPH – ProPhase Labs Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PRPH

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y